Stocks Health care VNDA
NASDAQ · Health careVanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. brought in $229.3M of revenue over the twelve months to September 30, 2026, up 8.1% from a year earlier. It posted a net loss of $274.8M. In fiscal 2025 capital spending exceeded operating cash flow by $110.4M. At September 30, 2026 it held $61.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Vanda Pharmaceuticals Inc.
- Net worth
- Vanda Pharmaceuticals Inc. has a market value (market cap) of $248.8M at the latest share price, and shareholders' equity of $199.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $216.1M (+8.7% year on year), with a net loss of $220.5M. Over the 12 months to September 30, 2026: revenue $229.3M, net loss $274.8M.
- Cash flow
- In fiscal 2025 operations used $109.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Vanda Pharmaceuticals Inc.'s next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Vanda Pharmaceuticals Inc. does
Vanda Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VNDA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $216.1M | -$220.5M | -$3.74 | -$110.4M |
| 2024 | $198.8M | -$18.9M | -$0.33 | -$16.2M |
| 2023 | $192.6M | $2.5M | $0.04 | $12.4M |
| 2022 | $254.4M | $6.3M | $0.11 | $31.3M |
| 2021 | $268.7M | $33.2M | $0.58 | $63.7M |
| 2020 | $248.2M | $23.3M | $0.42 | $50M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VNDA ranks in Health care
Latest SEC filings
What Vanda Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 24% to $69.8M versus the same quarter last year; diluted EPS -$0.37 versus -$0.38.
- October 28, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 9, 2026Passive stake changed SCHEDULE 13G/A
- August 19, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 3.9% to $50.5M versus the same quarter last year; diluted EPS -$1.04 versus -$0.46.
- August 5, 2026
- June 5, 2026
- June 5, 2026
Insider trades
What the people running Vanda Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $38.1K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Duncan Charles CliffDirector | Bought | 5,803 | $22.1K |
| November 4, 2026 | Duncan Charles CliffDirector | Bought | 3,447 | $13.2K |
| November 3, 2026 | Duncan Charles CliffDirector | Bought | 750 | $2.8K |
| June 4, 2026 | Mitchell Stephen RayDirector | Received as pay | 41,600 | - |
| June 4, 2026 | Honore TageDirector | Received as pay | 41,600 | - |
| June 4, 2026 | Ward Anne SempowskiDirector | Received as pay | 41,600 | - |
| June 4, 2026 | Dugan Richard WDirector | Received as pay | 41,600 | - |
| June 4, 2026 | Duncan Charles CliffDirector | Received as pay | 41,600 | - |
Who owns VNDA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Millennium Management LLC13G, passive with 2 related filers | 7% | October 9, 2026 |
| AQR Capital Management, LLC13G, passive with 1 related filers | 5.82% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 172 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 7,653,737 | +377,749 |
| State Street Corp | 3,516,405 | +500,843 |
| Aqr Capital Management LLC | 3,497,695 | +1,894,119 |
| Renaissance Technologies LLC | 3,441,361 | -318,198 |
| Vanguard Capital Management LLC | 2,524,040 | +42,549 |
| AIGH Capital Management LLC | 2,044,169 | -705,831 |
| Dimensional Fund Advisors LP | 1,727,349 | -44,244 |
| Millennium Management LLC | 1,602,813 | -278,188 |
| Geode Capital Management, LLC | 1,483,787 | +40,822 |
| Two Sigma Investments, LP | 1,349,072 | -49,129 |
| Marshall Wace, Llp | 1,225,996 | +629,994 |
| Jacobs Levy Equity Management, Inc | 1,213,326 | +44,645 |
| Vanguard Portfolio Management LLC | 1,131,034 | +116,512 |
| Goldman Sachs Group Inc | 1,036,260 | +198,027 |
| Citadel Advisors LLC | 758,302 | +124,948 |
| Qube Research & Technologies Ltd | 729,212 | new |
| Federated Hermes, Inc. | 714,278 | +138,889 |
| Charles Schwab Investment Management Inc | 646,256 | +94,486 |
| Northern Trust Corp | 600,619 | +149,638 |
| Morgan Stanley | 477,974 | +37,180 |
Insiders
12 insiders reported holding 5,332,261 shares in total, about $21.9M at the last price.
| Holder | Shares |
|---|---|
| Polymeropoulos Mihael HristosPresident and CEO, Director | 2,704,496 |
| Birznieks GuntherSVP, Business Development | 494,197 |
| Moran Kevin PatrickSVP, CFO & Treasurer | 411,380 |
| Williams TimothySVP & General Counsel | 377,450 |
| Wijkstrom JoakimSVP, Chief Marketing Officer | 333,469 |
| Dugan Richard WDirector | 219,054 |
| Chrousos PhaedraDirector | 164,950 |
| Ward Anne SempowskiDirector | 160,667 |
| Honore TageDirector | 135,069 |
| Mitchell Stephen RayDirector | 112,846 |
Questions about VNDA
What does Vanda Pharmaceuticals Inc. do?
Vanda Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as VNDA. Its shares trade on NASDAQ under the ticker VNDA.
What is Vanda Pharmaceuticals Inc.'s net worth?
Vanda Pharmaceuticals Inc. has a market value (market cap) of $248.8M at the latest share price, and shareholders' equity of $199.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vanda Pharmaceuticals Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $274.8M on revenue of $229.3M.
How much revenue does Vanda Pharmaceuticals Inc. make?
Over the twelve months to September 30, 2026 Vanda Pharmaceuticals Inc. reported revenue of $229.3M. That is 8.1% more than a year earlier.
When did Vanda Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Vanda Pharmaceuticals Inc.'s next earnings report?
Vanda Pharmaceuticals Inc.'s next report is expected around February 10, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VNDA with
Follow VNDA
Get an email when Vanda Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vanda Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.